Print Print Share Share #MISSING TRANSLATION: PageBar.SendToFriendTooltip# Email Large font-sizeNormal font-sizeSmall font-size

Publications

1 - 13 of 13 publications
  • 23 July 2009 /Retail and online sale

    Annual report on the inspection of retail sale of OTC medicines 2008-2009

    In 2008, the Danish Medicines Agency intensified its efforts on removing expired over-the-counter medicine from retail distribution.

  • 15 December 2009 /Prices and reimbursement

    Considerable increase in consumption of antidiabetic drugs from 1999 to 2008 in Denmark

    The number of people in Denmark being diagnosed with diabetes has soared for the past many years, and the same can be said for the sums spent on treatment and medicines for antidiabetics.

  • 17 April 2009 /About us

    Danish Medicines Agency annual accounts 2008

    In 2008, the Danish Medicines Agency achieved a target performance of 91.9 per cent in respect of the targets set out in the performance contract with the Danish Ministry of Health and Prevention, corresponding to a fulfillment of four in every five sub-requirements. Overall, we find that we delivered good technical results in 2008.

  • 30 July 2009 /Publications - miscellaneous

  • 13 July 2009 | Updated 27 August 2009 /Prices and reimbursement

    Effective effort against the excessive use of benzodiazepines in Denmark

    A long-term use of sleeping medicine and anti-anxiety drugs of the benzodiazepine type should be avoided, as it can lead to addiction, dizziness, memory impairment and concentration difficulties, as well as an increased risk of falling. Throough the years, many political health care initiatives have therefore been launched in order to reduce the consumption of these medicines.

  • 28 April 2009 /Prices and reimbursement

  • 03 July 2009 /About us

    Performance contract 2009

    The Danish Medicines Agency and the Ministry of Health and Prevention have agreed upon a performance contract, which is valid for 2009. The contract, which is in Danish only, focuses on external targets that cover the Danish Medicines Agency's tasks to the greatest extent possible.

  • 16 April 2009 /Authorisation and supervision

    Product defects and withdrawal of medicinal products in 2008

    In 2008, 177 reports of medicinal product defects were registered, which is less than in 2007. 23 % of these reports led to products being withdrawn from the market, which is also less than in the preceding years. Most of the withdrawals effected in 2008 were occasioned by reports made by the companies.

  • 02 September 2009 /Product areas

    Report on the blood product area in 2008

    The blood product report is published every year based on figures from the Danish blood centres and the Blood-donors in Denmark.

  • 28 May 2009 /Publications - miscellaneous

  • 01 December 2009 /Prices and reimbursement

    Sale of dose dispensed medicine in the primary Danish health sector 2004-2008

    Dose dispensing was launched in Denmark in 2002, and the use of dose dispensing has increased since then. Dose dispensing is used by all age groups, but the share of users increases with age, and women more frequently use dose dispensed medicine than men.

  • 17 June 2009 /Prices and reimbursement

    Sale of liberalised OTC medicines from 2001-2007

    The liberalisation of over-the-counter products (OTC medicines) may have contributed to an increase in the sale of smoking cessation products in the period from 2001-2007. With regard to the remaining medicinal products, there is nothing to suggest that the sale in general sales outlets has led to increased consumption.

  • 17 June 2009 /Prices and reimbursement

    Use of prescription weight-loss products from 2003-2007

    In recent years, the number of persons treated with prescription-only weight-loss products has increased, however, the total number of persons receiving treatment is lower than before 2002. The weight-loss products are primarily used by women aged between 35-55. In 2007, the number of users was affected by seasonal variations, which are more pronounced if we exclude persons who at the same time receive other medicines associated with overweight.